<DOC>
	<DOCNO>NCT00258232</DOCNO>
	<brief_summary>RATIONALE : Celecoxib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , capecitabine irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving celecoxib together capecitabine irinotecan may kill tumor cell . PURPOSE : This phase II trial study well give celecoxib together capecitabine irinotecan work treat patient recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>Celecoxib , Capecitabine , Irinotecan Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective response rate patient locally recurrent metastatic colorectal cancer treat celecoxib , capecitabine , irinotecan . Secondary - Determine time progression patient treat regimen . - Determine toxicity regimen patient . - Determine overall survival patient treat regimen . - Determine time treatment failure patient treat regimen . OUTLINE : This multicenter study . Patients receive oral celecoxib twice daily day -7 21 course 1 day 1-21 subsequent course . Patients also receive oral capecitabine twice daily day 1-14 irinotecan IV 30 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete partial response 4 course may temporarily discontinue treatment 4 week . After completion study treatment , patient follow every 6 month survival . PROJECTED ACCRUAL : A total 21-44 patient accrue study within 7-18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Locally recurrent metastatic disease Measurable disease , define ≥ 1 measurable lesion ≥ 20 mm conventional CT scan OR ≥ 10 mm spiral CT scan Bone metastasis , ascites , pleural effusion consider measurable disease Measurable lesion must locate outside previously irradiated field PATIENT CHARACTERISTICS : Performance status SWOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal No Gilbert 's disease Renal Creatinine clearance &gt; 50 mL/min Cardiovascular No clinically significant cardiac disease well control medication , include follow condition : Congestive heart failure Symptomatic coronary artery disease Cardiac arrhythmias No myocardial infarction within past year Gastrointestinal Must physically intact upper gastrointestinal tract Able swallow tablet No history peptic ulcer disease gastroesophageal reflux No malabsorption syndrome Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity No asthma , urticaria , allergictype reaction prior treatment aspirin nonsteroidal antiinflammatory drug No malignancy except curatively treated cancer evidence active disease No unresolved bacterial infection require antibiotic No serious infection No known allergy study drug sulfa drug PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy colorectal cancer Patients relapse &gt; 6 month completion prior adjuvant chemotherapy allow No concurrent anticancer chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 3 week since prior radiotherapy No concurrent anticancer radiotherapy Surgery Recovered prior surgery No concurrent anticancer surgery Other Prior celecoxib nonmalignant disorder allow No concurrent cyclooxygenase2 inhibitor nonsteroidal antiinflammatory drug , include follow : Rofecoxib Ibuprofen Naproxen Etodolac Oxaprozin Diflunisal Nabumetone Tolmetin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>